Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Caroline M. Robb, Smit Kour, Jacob I. Contreras, Ekta Agarwal, Carter J. Barger, Sandeep Rana, Yogesh Sonawane, Beth K. Neilsen, Margaret Taylor, Smitha Kizhake, Rhishikesh N. Thakare, Sanjib Chowdhury, Jing Wang, Jennifer D Black, Michael A Hollingsworth, Michael G. Brattain, Amarnath Natarajan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths in the United States. Currently, there are limited therapeutic options for patients suffering from CRC, none of which focus on the cell signaling mechanisms controlled by the popular kinase family, cyclin dependent kinases (CDKs). Here we evaluate a Pfizer developed compound, CP668863, that inhibits cyclin-dependent kinase 5 (CDK5) in neurodegenerative disorders. CDK5 has been implicated in a number of cancers, most recently as an oncogene in colorectal cancers. Our lab synthesized and characterized CP668863 - now called 20-223. In our established colorectal cancer xenograft model, 20-223 reduced tumor growth and tumor weight indicating its value as a potential anti-CRC agent. We subjected 20-223 to a series of cell-free and cell-based studies to understand the mechanism of its anti-tumor effects. In our hands, in vitro 20-223 is most potent against CDK2 and CDK5. The clinically used CDK inhibitor AT7519 and 20-223 share the aminopyrazole core and we used it to benchmark the 20-223 potency. In CDK5 and CDK2 kinase assays, 20-223 was ~3.5-fold and ~65.3-fold more potent than known clinically used CDK inhibitor, AT7519, respectively. Cell-based studies examining phosphorylation of downstream substrates revealed 20-223 inhibits the kinase activity of CDK5 and CDK2 in multiple CRC cell lines. Consistent with CDK5 inhibition, 20-223 inhibited migration of CRC cells in a wound-healing assay. Profiling a panel of CRC cell lines for growth inhibitory effects showed that 20-223 has nanomolar potency across multiple CRC cell lines and was on an average > 2-fold more potent than AT7519. Cell cycle analyses in CRC cells revealed that 20-223 phenocopied the effects associated with AT7519. Collectively, these findings suggest that 20-223 exerts anti-tumor effects against CRC by targeting CDK 2/5 and inducing cell cycle arrest. Our studies also indicate that 20-223 is a suitable lead compound for colorectal cancer therapy.

Original languageEnglish (US)
Pages (from-to)5216-5232
Number of pages17
JournalOncotarget
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Cyclin-Dependent Kinase 5
Colorectal Neoplasms
Cyclin-Dependent Kinases
Therapeutics
Phosphotransferases
Neoplasms
Cell Line
Cyclin-Dependent Kinase 2
Benchmarking
Growth
Cell Cycle Checkpoints
Tumor Burden
Oncogenes
Heterografts
Neurodegenerative Diseases
Wound Healing

Keywords

  • CDK inhibitor
  • Colorectal cancer (CRC)
  • Cyclin-dependent kinase (CDK)

ASJC Scopus subject areas

  • Oncology

Cite this

Robb, C. M., Kour, S., Contreras, J. I., Agarwal, E., Barger, C. J., Rana, S., ... Natarajan, A. (2018). Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget, 9(4), 5216-5232. https://doi.org/10.18632/oncotarget.23749

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. / Robb, Caroline M.; Kour, Smit; Contreras, Jacob I.; Agarwal, Ekta; Barger, Carter J.; Rana, Sandeep; Sonawane, Yogesh; Neilsen, Beth K.; Taylor, Margaret; Kizhake, Smitha; Thakare, Rhishikesh N.; Chowdhury, Sanjib; Wang, Jing; Black, Jennifer D; Hollingsworth, Michael A; Brattain, Michael G.; Natarajan, Amarnath.

In: Oncotarget, Vol. 9, No. 4, 01.01.2018, p. 5216-5232.

Research output: Contribution to journalArticle

Robb, CM, Kour, S, Contreras, JI, Agarwal, E, Barger, CJ, Rana, S, Sonawane, Y, Neilsen, BK, Taylor, M, Kizhake, S, Thakare, RN, Chowdhury, S, Wang, J, Black, JD, Hollingsworth, MA, Brattain, MG & Natarajan, A 2018, 'Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy', Oncotarget, vol. 9, no. 4, pp. 5216-5232. https://doi.org/10.18632/oncotarget.23749
Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S et al. Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 2018 Jan 1;9(4):5216-5232. https://doi.org/10.18632/oncotarget.23749
Robb, Caroline M. ; Kour, Smit ; Contreras, Jacob I. ; Agarwal, Ekta ; Barger, Carter J. ; Rana, Sandeep ; Sonawane, Yogesh ; Neilsen, Beth K. ; Taylor, Margaret ; Kizhake, Smitha ; Thakare, Rhishikesh N. ; Chowdhury, Sanjib ; Wang, Jing ; Black, Jennifer D ; Hollingsworth, Michael A ; Brattain, Michael G. ; Natarajan, Amarnath. / Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. In: Oncotarget. 2018 ; Vol. 9, No. 4. pp. 5216-5232.
@article{b23db5aa15db4a008ac13bed0ca00b38,
title = "Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy",
abstract = "Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths in the United States. Currently, there are limited therapeutic options for patients suffering from CRC, none of which focus on the cell signaling mechanisms controlled by the popular kinase family, cyclin dependent kinases (CDKs). Here we evaluate a Pfizer developed compound, CP668863, that inhibits cyclin-dependent kinase 5 (CDK5) in neurodegenerative disorders. CDK5 has been implicated in a number of cancers, most recently as an oncogene in colorectal cancers. Our lab synthesized and characterized CP668863 - now called 20-223. In our established colorectal cancer xenograft model, 20-223 reduced tumor growth and tumor weight indicating its value as a potential anti-CRC agent. We subjected 20-223 to a series of cell-free and cell-based studies to understand the mechanism of its anti-tumor effects. In our hands, in vitro 20-223 is most potent against CDK2 and CDK5. The clinically used CDK inhibitor AT7519 and 20-223 share the aminopyrazole core and we used it to benchmark the 20-223 potency. In CDK5 and CDK2 kinase assays, 20-223 was ~3.5-fold and ~65.3-fold more potent than known clinically used CDK inhibitor, AT7519, respectively. Cell-based studies examining phosphorylation of downstream substrates revealed 20-223 inhibits the kinase activity of CDK5 and CDK2 in multiple CRC cell lines. Consistent with CDK5 inhibition, 20-223 inhibited migration of CRC cells in a wound-healing assay. Profiling a panel of CRC cell lines for growth inhibitory effects showed that 20-223 has nanomolar potency across multiple CRC cell lines and was on an average > 2-fold more potent than AT7519. Cell cycle analyses in CRC cells revealed that 20-223 phenocopied the effects associated with AT7519. Collectively, these findings suggest that 20-223 exerts anti-tumor effects against CRC by targeting CDK 2/5 and inducing cell cycle arrest. Our studies also indicate that 20-223 is a suitable lead compound for colorectal cancer therapy.",
keywords = "CDK inhibitor, Colorectal cancer (CRC), Cyclin-dependent kinase (CDK)",
author = "Robb, {Caroline M.} and Smit Kour and Contreras, {Jacob I.} and Ekta Agarwal and Barger, {Carter J.} and Sandeep Rana and Yogesh Sonawane and Neilsen, {Beth K.} and Margaret Taylor and Smitha Kizhake and Thakare, {Rhishikesh N.} and Sanjib Chowdhury and Jing Wang and Black, {Jennifer D} and Hollingsworth, {Michael A} and Brattain, {Michael G.} and Amarnath Natarajan",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23749",
language = "English (US)",
volume = "9",
pages = "5216--5232",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "4",

}

TY - JOUR

T1 - Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

AU - Robb, Caroline M.

AU - Kour, Smit

AU - Contreras, Jacob I.

AU - Agarwal, Ekta

AU - Barger, Carter J.

AU - Rana, Sandeep

AU - Sonawane, Yogesh

AU - Neilsen, Beth K.

AU - Taylor, Margaret

AU - Kizhake, Smitha

AU - Thakare, Rhishikesh N.

AU - Chowdhury, Sanjib

AU - Wang, Jing

AU - Black, Jennifer D

AU - Hollingsworth, Michael A

AU - Brattain, Michael G.

AU - Natarajan, Amarnath

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths in the United States. Currently, there are limited therapeutic options for patients suffering from CRC, none of which focus on the cell signaling mechanisms controlled by the popular kinase family, cyclin dependent kinases (CDKs). Here we evaluate a Pfizer developed compound, CP668863, that inhibits cyclin-dependent kinase 5 (CDK5) in neurodegenerative disorders. CDK5 has been implicated in a number of cancers, most recently as an oncogene in colorectal cancers. Our lab synthesized and characterized CP668863 - now called 20-223. In our established colorectal cancer xenograft model, 20-223 reduced tumor growth and tumor weight indicating its value as a potential anti-CRC agent. We subjected 20-223 to a series of cell-free and cell-based studies to understand the mechanism of its anti-tumor effects. In our hands, in vitro 20-223 is most potent against CDK2 and CDK5. The clinically used CDK inhibitor AT7519 and 20-223 share the aminopyrazole core and we used it to benchmark the 20-223 potency. In CDK5 and CDK2 kinase assays, 20-223 was ~3.5-fold and ~65.3-fold more potent than known clinically used CDK inhibitor, AT7519, respectively. Cell-based studies examining phosphorylation of downstream substrates revealed 20-223 inhibits the kinase activity of CDK5 and CDK2 in multiple CRC cell lines. Consistent with CDK5 inhibition, 20-223 inhibited migration of CRC cells in a wound-healing assay. Profiling a panel of CRC cell lines for growth inhibitory effects showed that 20-223 has nanomolar potency across multiple CRC cell lines and was on an average > 2-fold more potent than AT7519. Cell cycle analyses in CRC cells revealed that 20-223 phenocopied the effects associated with AT7519. Collectively, these findings suggest that 20-223 exerts anti-tumor effects against CRC by targeting CDK 2/5 and inducing cell cycle arrest. Our studies also indicate that 20-223 is a suitable lead compound for colorectal cancer therapy.

AB - Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths in the United States. Currently, there are limited therapeutic options for patients suffering from CRC, none of which focus on the cell signaling mechanisms controlled by the popular kinase family, cyclin dependent kinases (CDKs). Here we evaluate a Pfizer developed compound, CP668863, that inhibits cyclin-dependent kinase 5 (CDK5) in neurodegenerative disorders. CDK5 has been implicated in a number of cancers, most recently as an oncogene in colorectal cancers. Our lab synthesized and characterized CP668863 - now called 20-223. In our established colorectal cancer xenograft model, 20-223 reduced tumor growth and tumor weight indicating its value as a potential anti-CRC agent. We subjected 20-223 to a series of cell-free and cell-based studies to understand the mechanism of its anti-tumor effects. In our hands, in vitro 20-223 is most potent against CDK2 and CDK5. The clinically used CDK inhibitor AT7519 and 20-223 share the aminopyrazole core and we used it to benchmark the 20-223 potency. In CDK5 and CDK2 kinase assays, 20-223 was ~3.5-fold and ~65.3-fold more potent than known clinically used CDK inhibitor, AT7519, respectively. Cell-based studies examining phosphorylation of downstream substrates revealed 20-223 inhibits the kinase activity of CDK5 and CDK2 in multiple CRC cell lines. Consistent with CDK5 inhibition, 20-223 inhibited migration of CRC cells in a wound-healing assay. Profiling a panel of CRC cell lines for growth inhibitory effects showed that 20-223 has nanomolar potency across multiple CRC cell lines and was on an average > 2-fold more potent than AT7519. Cell cycle analyses in CRC cells revealed that 20-223 phenocopied the effects associated with AT7519. Collectively, these findings suggest that 20-223 exerts anti-tumor effects against CRC by targeting CDK 2/5 and inducing cell cycle arrest. Our studies also indicate that 20-223 is a suitable lead compound for colorectal cancer therapy.

KW - CDK inhibitor

KW - Colorectal cancer (CRC)

KW - Cyclin-dependent kinase (CDK)

UR - http://www.scopus.com/inward/record.url?scp=85040451578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040451578&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23749

DO - 10.18632/oncotarget.23749

M3 - Article

C2 - 29435174

AN - SCOPUS:85040451578

VL - 9

SP - 5216

EP - 5232

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 4

ER -